Diamant Thaçi1, Pablo de la Cueva2, Andrew E Pink3, Ahmad Jalili4, Siegfried Segaert5, Kasper F Hjuler6, Piergiacomo Calzavara-Pinton7. 1. Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany. 2. Department of Dermatology, University Hospital Infanta Leonor de Madrid, Madrid, Spain. 3. St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK. 4. Department of Dermatology, Bürgenstock Medical Center, Obbürgen, Switzerland. 5. Consultant Dermatologist, Bonheiden, Belgium. 6. Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark. 7. Department of Dermatology, University of Brescia, Brescia, Italy piergiacomo.calzavarapinton@unibs.it.
Abstract
BACKGROUND: Although GPs are usually the first port of call for patients with psoriasis, there is a lack of consistent and up-to-date clinical recommendations for interventions for patients with mild-to-moderate disease. AIM: To provide practical recommendations for GPs to optimise psoriasis treatment with topical therapies in four key areas: patient identification; treatment decision making with topical theory; topical treatment outcomes; and optimising patient adherence. DESIGN & SETTING: A consensus-seeking programme (modified-Delphi approach) was undertaken to assess the literature and develop recommendations for GPs, based on evidence and expert opinion. METHOD: Three dermatologists compiled 47 questions that were subsequently ranked and refined according to clinical relevance or importance using an online survey. Thereafter, 19 dermatologists from different European countries developed statements and clinical recommendations for the top seven ranked topical treatment and GP-relevant questions based on literature research and clinical experience. The final recommendations were based on 100% agreement among a final panel of seven experts. RESULTS: The clinical effectiveness, fast onset of action, tolerability, cosmetic acceptability, and practicability of topical therapy, in addition to good physician-patient communication, are important for optimising patient adherence and maximising efficacy. Topical treatments combining corticosteroids and vitamin D analogues (administered as fixed combination) are well-established first-line treatments in mild-to-moderate psoriasis. CONCLUSION: Simple but detailed practical guidance is provided, which is formed from evidence and expert clinical recommendations, to assist GPs with the optimal use of topical agents based on efficacy, tolerability, disease severity, site of psoriasis, patient lifestyle and preferences, and intended duration of treatment.
BACKGROUND: Although GPs are usually the first port of call for patients with psoriasis, there is a lack of consistent and up-to-date clinical recommendations for interventions for patients with mild-to-moderate disease. AIM: To provide practical recommendations for GPs to optimise psoriasis treatment with topical therapies in four key areas: patient identification; treatment decision making with topical theory; topical treatment outcomes; and optimising patient adherence. DESIGN & SETTING: A consensus-seeking programme (modified-Delphi approach) was undertaken to assess the literature and develop recommendations for GPs, based on evidence and expert opinion. METHOD: Three dermatologists compiled 47 questions that were subsequently ranked and refined according to clinical relevance or importance using an online survey. Thereafter, 19 dermatologists from different European countries developed statements and clinical recommendations for the top seven ranked topical treatment and GP-relevant questions based on literature research and clinical experience. The final recommendations were based on 100% agreement among a final panel of seven experts. RESULTS: The clinical effectiveness, fast onset of action, tolerability, cosmetic acceptability, and practicability of topical therapy, in addition to good physician-patient communication, are important for optimising patient adherence and maximising efficacy. Topical treatments combining corticosteroids and vitamin D analogues (administered as fixed combination) are well-established first-line treatments in mild-to-moderate psoriasis. CONCLUSION: Simple but detailed practical guidance is provided, which is formed from evidence and expert clinical recommendations, to assist GPs with the optimal use of topical agents based on efficacy, tolerability, disease severity, site of psoriasis, patient lifestyle and preferences, and intended duration of treatment.
Authors: Alan Menter; Bruce E Strober; Daniel H Kaplan; Dario Kivelevitch; Elizabeth Farley Prater; Benjamin Stoff; April W Armstrong; Cody Connor; Kelly M Cordoro; Dawn M R Davis; Boni E Elewski; Joel M Gelfand; Kenneth B Gordon; Alice B Gottlieb; Arthur Kavanaugh; Matthew Kiselica; Neil J Korman; Daniela Kroshinsky; Mark Lebwohl; Craig L Leonardi; Jason Lichten; Henry W Lim; Nehal N Mehta; Amy S Paller; Sylvia L Parra; Arun L Pathy; Reena N Rupani; Michael Siegel; Emily B Wong; Jashin J Wu; Vidhya Hariharan; Craig A Elmets Journal: J Am Acad Dermatol Date: 2019-02-13 Impact factor: 11.527
Authors: A Jalili; M Lebwohl; L Stein Gold; S B Andersen; K L Jensen; A E Pink; S Segaert; P Berg; P G Calzavara-Pinton; P de la Cueva Dobao; D Thaçi Journal: J Eur Acad Dermatol Venereol Date: 2019-04 Impact factor: 6.166
Authors: K Reich; I Zschocke; H Bachelez; E M G J de Jong; P Gisondi; L Puig; R B Warren; C Ortland; U Mrowietz Journal: Br J Dermatol Date: 2017-06-06 Impact factor: 9.302
Authors: Craig Leonardi; Jerry Bagel; Paul Yamauchi; David Pariser; Zhenyi Xu; Martin Olesen; Marie Louise Østerdal; Linda Stein Gold Journal: J Drugs Dermatol Date: 2015-12 Impact factor: 2.114
Authors: C Paul; L Stein Gold; F Cambazard; R E Kalb; D Lowson; B Bang; C E M Griffiths Journal: J Eur Acad Dermatol Venereol Date: 2016-08-17 Impact factor: 6.166
Authors: Pauline A Nelson; Zoë Barker; Christopher E M Griffiths; Lis Cordingley; Carolyn A Chew-Graham Journal: BMC Fam Pract Date: 2013-10-20 Impact factor: 2.497